Neurology Edition: Top Headlines for Week of May 23, 2023

In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer’s and more.

Read the full coverage here:

FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation

Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment

Leqembi reduced biomarkers of Alzheimer’s, slowed cognitive decline at 18 months

FDA grants 510(k) clearance for self-directed EEG headset

Oral Bruton’s tyrosine kinase inhibitor reduced brain lesions in phase 2 MS trial

References:

Altomare D, et al. JAMA Neurol. 2023;doi:10.1001/jamaneurol.2023.0997.

Press Release

Press Release

Press Release

Van Dyck CH, et al. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer’s disease (Clarity AD). Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.